Kimberly-Clark acquires Neutrogena-owner Kenvue
Kimberly-Clark is laying down $40 billion to buy Kenvue in a massive deal that has puzzled some investors as the Tylenol maker struggles with weak sales and White House attacks linking its painkiller to autism.
